COLODNER R, KENESS Y, CHAZAN B, RAZ R; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. L-1059.
HaEmek Medical Center, Afula, Israel
BACKGROUND: The prevalence of extended spectrum beta-lactamase (ESBL) producing E. coli and Klebsiella sp. outside the hospital setting as causes of community acquired urinary tract infections (CA-UTI) has remarkably increased in the last few years. Since the presence of ESBL+ coincides with a wide range resistance pattern to antimicrobials, its treatment has became more and more challenging. In this study, the susceptibility pattern of ESBL+ E. coli and Klebsiella sp. isolated from CA-UTI are presented. METHODS: Identification and susceptibility of E. coli and Klebsiella sp. isolated from CA-UTI urine samples were peformed using Microscan Urine Combo 2 panels and a WalkAway 96 system. Isolates suspected as potential ESBL producers were confirmed by E-test using ceftazidime and cefotaxime with and without clavulanate. The susceptibility pattern of 105 confirmed ESBL producers was analyzed and MIC[90] was calculated. RESULTS: [table: see text] CONCLUSIONS: Nitrofurantoin and amoxi-clavulanate are both a good choice for the treatment of CA-UTI due to ESBL+ E. coli, however Klebsiella sp. proved only moderate susceptibility rate to these drugs. Fluoroquinolones are an acceptable alternative for ESBL+ Klebsiella sp. though only a third of ESBL+ E. coli isolates were suceptible to them. Gentamicin proved to be effective to only one third of ESBL+ E. coli isolates.
Publication Types:
Keywords:
- Anti-Infective Agents
- Clavulanic Acid
- Klebsiella
- Klebsiella Infections
- Microbial Sensitivity Tests
- Urinary Tract Infections
Other ID:
UI: 102270623
From Meeting Abstracts